Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial

Michael Organ; Lori Wood; Derek Wilke; Chris Skedgel; Tina Cheng; Scott North; Kara Thompson; Susan Winch; Ricardo Rendon

doi:10.1097/COC.0b013e31825d5664

Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial

Michael Organ, Lori Wood, Derek Wilke, Chris Skedgel, Tina Cheng, Scott North, Kara Thompson, Susan Winch, Ricardo Rendon

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.

Original language	English
Pages (from-to)	601-605
Number of pages	5
Journal	American Journal of Clinical Oncology
Volume	36
Issue number	6
DOIs	https://doi.org/10.1097/COC.0b013e31825d5664
Publication status	Published - Dec 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aged
Aged, 80 and over
Costs and Cost Analysis
Follow-Up Studies
Gonadotropin-Releasing Hormone
Humans
Male
Middle Aged
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant
Quality of Life
Questionnaires
Testosterone
Treatment Outcome

Access to Document

10.1097/COC.0b013e31825d5664

Cite this

Organ, M., Wood, L., Wilke, D., Skedgel, C., Cheng, T., North, S., Thompson, K., Winch, S., & Rendon, R. (2013). Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. American Journal of Clinical Oncology, 36(6), 601-605. https://doi.org/10.1097/COC.0b013e31825d5664

@article{58cf80550e634550950af847af7285dd,

title = "Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial",

abstract = "Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.",

keywords = "Aged, Aged, 80 and over, Costs and Cost Analysis, Follow-Up Studies, Gonadotropin-Releasing Hormone, Humans, Male, Middle Aged, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Quality of Life, Questionnaires, Testosterone, Treatment Outcome",

author = "Michael Organ and Lori Wood and Derek Wilke and Chris Skedgel and Tina Cheng and Scott North and Kara Thompson and Susan Winch and Ricardo Rendon",

year = "2013",

month = dec,

doi = "10.1097/COC.0b013e31825d5664",

language = "English",

volume = "36",

pages = "601--605",

journal = "American Journal of Clinical Oncology",

issn = "1537-453X",

publisher = "Lippincott, Williams and Wilkins",

number = "6",

}

Organ, M, Wood, L, Wilke, D, Skedgel, C, Cheng, T, North, S, Thompson, K, Winch, S & Rendon, R 2013, 'Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial', American Journal of Clinical Oncology, vol. 36, no. 6, pp. 601-605. https://doi.org/10.1097/COC.0b013e31825d5664

TY - JOUR

T1 - Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa)

T2 - results of a multi-institutional randomized prospective clinical trial

AU - Organ, Michael

AU - Wood, Lori

AU - Wilke, Derek

AU - Skedgel, Chris

AU - Cheng, Tina

AU - North, Scott

AU - Thompson, Kara

AU - Winch, Susan

AU - Rendon, Ricardo

PY - 2013/12

Y1 - 2013/12

N2 - Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.

AB - Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.

KW - Aged

KW - Aged, 80 and over

KW - Costs and Cost Analysis

KW - Follow-Up Studies

KW - Gonadotropin-Releasing Hormone

KW - Humans

KW - Male

KW - Middle Aged

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms, Castration-Resistant

KW - Quality of Life

KW - Questionnaires

KW - Testosterone

KW - Treatment Outcome

U2 - 10.1097/COC.0b013e31825d5664

DO - 10.1097/COC.0b013e31825d5664

M3 - Article

C2 - 22868247

SN - 1537-453X

VL - 36

SP - 601

EP - 605

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

IS - 6

ER -